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ABSTRACT 
The explosive growth in genetic technology will quickly make possible an 
unprecedented number of tests for genetically based conditions.  A 
necessary condition for the use of such tests without risk of harm to the 
patient is that they are “accurate”.  However, most discussions of test 
accuracy in the literature have equivocated between two importantly 
different meanings of the word.  In particular, it must be kept in mind that 
a high analytical accuracy does not imply a high diagnostic accuracy.  
Questions about the diagnostic accuracy of genetic tests loom large at 
present given our limited knowledge of the complex etiology of disease 
and the distribution within the general population of the causal factors 
involved.   Our current inability to supply patients with accurate diagnosis 
based on genetic information, however, is less problematic when 
examined in the context of new reproductive technologies such as in vitro 
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“For every complex problem, there is a simple, easy to understand, 
incorrect answer.” 
        -- Albert Szent-Gyorgyi 
 
I.  INTRODUCTORY COMMENTS 
   The growth in genetic testing technology is nothing short of explosive.  
The Human Genome Project, which aims to sequence all 100,000 human 
genes, is currently ahead of schedule and should be complete by the 
year 2001 -- some even predict that we will have the sequence for all 
genes in all living organisms by 2015 if sequencing efforts continue to grow  
at the present rate (1).   Within the next 10 years, as many as 400 new 
genetic screens are likely to become available, aided by development of 
integrated circuit chips capable of performing thousands of hybridization 
probes on a single minute sample of DNA.   Already, more than 4 million 
blood samples from newborn heel sticks are screened each year for 
various genetic disorders (2).    Genetic screening is thus likely to be 
increasingly viewed as a common and  accepted aspect of modern 
medicine, based in large part on the perception that offering patients 
screening is itself a harmless enterprise, and may even be required as part 
of the standard of care1.  However, offering genetic screening is often 
only harmless to the extent that it provides an accurate basis for making 
informed decisions about one’s condition.2 
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II. INFORMATION AND ACCURACY OF GENERALIZED GENETIC SCREENING 
   I do not mean to suggest that genetic screening is inherently evil, much 
less that it is avoidable.   It is also beyond the scope of the present work to 
address all the various social and ethical issues that the widespread use of 
genetic screening in the general population will surely raise: access to 
insurance, privacy, social stigmatization, eugenics, etc.   However, I do 
want to draw attention to a problem with genetic screening when it is 
applied to the general population which has not received as much 
attention in the literature as it deserves3. 
   The problem is that discussions of the accuracy of genetic testing often 
equivocate between two distinct meanings of  “accuracy”.   With our 
current state of knowledge, a high degree of analytic accuracy in a 
genetic test does not imply a similarly high degree of diagnostic 
accuracy4.  By “analytic accuracy” I mean the accuracy with which a 
test identifies the presence of the gene it is designed to locate -- avoiding 
both  positive results when the gene is absent and negative results when 
the gene is present.   By “diagnostic accuracy” I mean the accuracy with 
which the test can be used to make predictions about a patient’s 
prognosis.   For the sake of argument, let’s assume that we are only 
discussing tests which have a 100% analytic accuracy. That is, we have 
somehow managed to avoid the problems posed by laboratory error and 
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we are testing directly for the gene in question, not a closely linked 
marker5.  Even in this ideal case, interpreting the results of the test in a way 
that is meaningful to patients will be extremely difficult for a long while to 
come. 
   At its most basic, the reason for this can be stated as follows:  the 
presence of a particular gene associated with a medical condition does 
not insure that one will develop the condition6.  There are three possible 
explanations for this lack of “genetic determinism”:  multiple mutations 
(alleles) for a single gene, multiple genes, and gene-environment 
interactions.   If the genetic basis of a condition has many alleles and their 
frequencies vary widely between populations, then the type of test 
required and the way the results are interpreted are relative to the 
population from which the patient comes in complex ways.  If the 
condition has multiple genes, then we will need to determine all or most 
of the genes involved and test for each of them simultaneously to obtain 
an accurate diagnosis.  Finally, if the condition exhibits significant gene-
environment interaction -- as is the case with most complex medical 
conditions and particularly those involving “propensity genes” (e.g., 
cancer, coronary disease, etc.) -- we must be able to assess the variation 
of significant environmental factors within the patient population to be 
screened in  order to make diagnostic predictions7. 
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   It is important to keep in mind that this is more than the obvious point 
that, “one can never predict things with absolute certainty.”  With current 
techniques, it is very difficult even to assign an accurate probability to a 
particular diagnosis8, though this seems a minimum requirement for the 
justification of testing in the first place.  One way to illustrate the problem is 
by looking at the procedure most often initially used to isolate a gene 
associated with a medical condition.  Since such conditions are typically 
quite rare, the first step is to locate a population in which the condition is 
unusually common so that we have more of a phenomenon to study.  
Then, researchers conduct statistical analyses to see if there are any 
regions of the chromosomes which seem to covary significantly with the 
condition -- that is, if there are any pieces of genetic material one is 
significantly more likely to have if one has the condition than if one is 
healthy.  Once we have located a segment of DNA that appears to 
covary with the condition, we can use molecular techniques to refine the 
analysis.  In the ideal case,  these efforts will isolate a single gene which is 
then designated as “the gene for” the condition.   At this point, we can 
develop genetic tests to determine if  individuals have the gene9, but can 
we make accurate diagnostic predictions about the likelihood of their 
developing the condition? 
   Suppose, for example, I find that in populations of Eastern European 
(Ashkenazi) Jews, there is a very high incidence of breast cancer 
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associated with a particular gene (BRCA1).  Fully 85% of Ashkenazi women 
with BRCA1 will develop breast or ovarian cancer in their lifetimes.  Now 
suppose I produce a test for BRCA1 and administer it to women in the 
general population.  If a woman who is neither Jewish nor European tests 
positive for BRCA1, do I tell her that she has an 85% chance of contracting 
cancer?  Such a prediction is justifiable only if one of two assumptions is 
correct: 
 1)  There are no other factors besides the BRCA1 gene which 
 significantly  alter the likelihood of developing cancer. 
    2) There are other factors which significantly alter the likelihood of 
 developing cancer, but these have the same distribution in the 
 general population as they do in the Ashkenazi population and 
 therefore do not differentially affect the likelihood of developing 
 the condition from one population to the other. 
  The first assumption is almost certainly false for a condition like cancer 
which probably involves multiple genes with multiple alleles and complex 
gene-environment interactions all at once.  So, is the second assumption 
true?   If we are honest, we should admit that we really don’t know; both 
because we do not know all the causal factors which influence cancer 
and because, even if we did know them all, we have not measured their 
distribution within the general population.   Moreover, the population in 
which we conducted the initial study was attractive precisely because it 
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was NOT representative -- in particular, it had an unusually  high incidence 
of the rare disorder and associated gene(s).  But the same factors which 
produced this biased distribution in the study population (e.g., inbreeding) 
are almost certain to have skewed distributions of other factors as well.  So 
the study population is unlikely to have a “normal” distribution of whatever 
additional factors may be causally influencing the condition -- whether 
they be genetic, cytoplasmic or environmental.  The diagnostic accuracy 
of the test with respect to the general population is entirely dependent on 
the questionable assumption of a uniform distribution of causal factors 
and is thus suspect -- despite the fact that we have (ex hypothesi) a test 
with perfect analytical accuracy. 
 
III.  CYSTIC FIBROSIS AS A CASE STUDY 
   Cystic Fibrosis (CF) makes a good case study for the type of problem I 
want to highlight for several reasons.  For one thing, it has a relatively 
simple etiology as genetic conditions go in that there seems to be just a 
single gene involved.  For another, it is relatively common -- about 1 out of 
every 2,500 whites of European descent is affected10.  Lastly, it is one of 
the few genetic conditions for which there is data on the population 
distribution of the alleles involved (as well as the effectiveness of 
education programs). 
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   CF is a condition in which thickened secretions in the respiratory, 
digestive and reproductive systems result in chronic respiratory infections, 
loss of respiratory function, digestive difficulties and infertility.  It can be an 
extremely debilitating condition and is often fatal, though the median 
survival has now climbed to forty years old and approximately one half of 
CF patients survive into their fifties (with intensive therapy).   It is caused by 
various recessive autosomal mutations in the gene which codes for the 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, of 
which there are known to be more than 300 alleles11.   Since the majority 
of mutant alleles are carried by people who are heterozygous (and thus 
don’t exhibit the recessive disease), as many as one in every thirty U.S. 
citizens (3% of the general population) may carry at least a single copy of 
a CF mutation.   
   CF can  be diagnosed in three different ways: through an assessment of 
symptomology/physiologic performance, through the sweat chloride test, 
and through genetic testing for a known mutant allele.  Since fully 85% of 
CF cases occur in families with no known history of the condition, it has 
been proposed as a desirable candidate for generalized screening of the 
population (12, but see also 13). 
   As Table 1 shows, however, just about every combination of diagnostic 
indicators has been documented12.   There is also no simple relationship 
between particular genetic alleles and the severity of the disease (11, 15, 
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16).  Thus, on the basis of genetic tests and/or sweat chloride values, it is 
very difficult to predict whether a patient will develop the condition and 
how severely he will be affected.   Lastly, there are large differences 
between populations with respect to the relative frequency of the alleles 
and quite different screens are often required for different populations.  
Even for what most people intuitively consider a homogenous population, 
white Europeans, genetic diversity is the rule rather than the exception.  
For example, screening for just 4 alleles in Britain is sufficient to detect 85% 
of CF cases -- but in Southern Europe, screening for as many as 60 
mutations detects only 75% of the CF cases13. 
   Therefore, even for a “single gene” condition like CF, it is not enough 
simply to identify all the alleles which are associated with the condition.  
We must also assess their distribution in various populations and reliably 
determine into which population a patient should be classed.14  All three 
tasks present complex problems which require a great deal more work to 
solve adequately15. 
 
IV.  THE PSYCHOLOGY OF INFORMATION 
   Above and beyond the information problems discussed above, there 
are additional problems with the way the genetic results will be 
perceived.  There is a strong psychological tendency to view numerical 
information as being highly accurate, despite the fact that the actual 
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information content of such numbers can range from 0 (completely 
uninformative) to 1 (perfect predictor).  In the case of genetic screening, 
the information content of numerical diagnostic predictions is typically 
unknown or, at the very least, subject to debate.  To be sure, this is not a 
problem limited to the lay public as even professional logicians and 
statisticians often make elementary errors in interpreting information -- 
particularly statistical information (19). 
   However, in the context of genetic screening, this problem looms 
particularly large.   We wish patients to be actively involved with their own 
treatment and require informed consent for any medical procedure done 
to a patient that might inflict harm.  The ideal case is for the patient to 
assess the risks and benefits for herself and decide whether to undergo 
the procedure.   To what extent can this ideal be met in the case of 
genetic screening? 
   The first question is,  “Can the patient be made to understand the 
relevant details of a highly technical procedure like genetic screening?”  
The evidence suggests that, with a great deal of effort by trained genetic 
counselors, they can (20).   This is encouraging, though it must be kept in 
mind that there is currently a severe shortage of trained counselors.  Thus, 
if screening becomes commonplace, it will be increasingly performed by 
general practitioners whose training in genetics and probability is not of 
uniformly high quality16.                                                 
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    The next question is, “Are people able to retain the information 
accurately beyond the immediate context of testing?”  Here, the 
evidence is less encouraging.  In one three year follow-up to large-scale 
CF screening, it was found that 20% of those identified as carriers 
incorrectly recalled the results of the testing.  Moreover, of those who 
correctly recalled the result, 46% interpreted it incorrectly as meaning that 
they were only likely to be carriers (20).  It has been suggested that this 
problem may ultimately be correctable by changes in the educational 
system to produce graduates who are better informed about genetics 
and statistics17, but this is certainly a very long term project. 
   The last question is, “Do people actually want the tests?”  The answer to 
this is complex.  Offers of free genetic screening to members of the 
general population typically result in very low response rates, suggesting 
that many people have little desire to know their genetic status (23).  On 
the other hand, it’s been found that fully 70% of those offered screening in 
person by a health professional accept (6).  Whether a patient accepts a 
test depends strongly on the mode of presentation18, and this brings up 
the issue of whether even the offer of genetic testing by a physician is, in 
fact, a neutral act.  It seems likely that such an offer will be perceived by 
the patient as constituting at least an indication of safety and accuracy, 
and perhaps even an endorsement of value.   If so, this will significantly 
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strengthen the perception that the resulting diagnostic prediction is highly 
accurate. 
 
V. GENETIC SCREENING AND REPRODUCTIVE TECHNOLOGY 
A. Pre-natal Screening 
   One of the most obvious and compelling but also most controversial 
applications of genetic screening is its use in pre-natal care.   It is 
compelling because we are deeply concerned with the health of our 
children -- often more so than with our own (as any pediatrician can 
testify).  It is controversial because, although there is always the hope that 
early detection will allow early intervention, this is currently quite rare19 
and thus the main outcome of a “bad” genetic result is termination of the 
pregnancy.    
   Two techniques of obtaining tissue samples for genetic analysis are 
currently widely used.  Amniocentesis is performed at 14-16 weeks of 
gestation and involves needle aspiration of amniotic fluid containing fetal 
cells.  The cells are then cultured and their DNA analyzed.  Chorionic Villus 
Sampling (CVS) is performed at 9-12 weeks gestation and involves 
collection of cells from the chorion (either by catheter or needle), which 
can then be immediately analyzed.  CVS is a major improvement over 
amniocentesis in that the procedure can be performed much earlier and 
the results obtained more quickly (24 hours as opposed to 10-14 days).   
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   Both procedures are highly invasive and carry small but significant risk to 
the fetus (approximately 1% risk of fetal loss).  Moreover, some conditions 
can not currently be detected at eight weeks (e.g., some neural tube 
defects).  For these reasons, it is unlikely that genetic screening using these 
tissue collection techniques will ever become standard procedure for the 
vast majority of pregnancies.  However,  this is all likely to change soon as 
new techniques for isolating fetal cells from maternal blood samples 
come on line (24).  It is now possible to detect and isolate fetal cells in the 
maternal blood as early as 9 weeks gestation20.   
   As little as fifteen years ago, it would have been impossible to perform 
genetic analysis on the vanishingly small amounts of DNA obtained from 
such a tiny sample of cells, but the newly-developed Polymerase Chain 
Reaction (PCR) technique is capable of amplifying DNA from a single cell 
quickly and accurately.   Moreover, as the Human Genome Project 
reaches completion and more and more genes are identified, it will be 
possible to screen very early fetal cells for their genetic contents.   What 
this means in practice is that soon there will be techniques which are 
available very early in pregnancy and are no more invasive or dangerous 
than a routine blood sample.  Under these circumstances, it seems very 
likely that they will quickly become an accepted part of standard care. 
 
B. Pre-implantation Screening 
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   With In Vitro Fertilization (IVF), it is now possible to test extremely early 
embryos for genetic conditions.   In IVF, multiple donated eggs are 
collected and mixed with donated semen in vitro.  It is possible to remove 
a single cell at the 4 or 8 cell stage of the resulting embryo and, using PCR, 
amplify and analyze its genes.   In fact, it is possible to detect some 
genetic abnormalities in a single-celled zygote using Fluorescent In Situ 
Hybridization (FISH).  FISH involves treating the cell with fluorescent genetic 
probes which will hybridize to some kinds of genetic abnormalities, making 
the deformity visible under a microscope21. 
   Although early detection is a major advantage, IVF is also extremely 
invasive.  The costs, both emotional and economic, are quite high -- with 
success rates of approximately 14% per procedure and costs of $15,000 
(2).  IVF pre-implantation screening will thus remain a specialized 
procedure for the present22. 
 
C. Pre-fertilization Screening 
   Techniques for the screening of individual gametes are currently under 
development.  If techniques like FISH eventually make it possible to certify 
samples of sperm or eggs as “defect free”, this would constitute the 
ultimate in screening.   For one thing, it offers advantages over  screening 
of the parents since, even if both parents are carriers of a recessive 
condition, there is only a 25% chance the child will exhibit the condition 
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(and a 50% chance the child will also be a carrier).  For another, it avoids 
the issue of termination of pregnancy since undesirable pregnancies will 
not even be started.  At the very least, the technique is likely to become 
popular with sperm donated to sperm banks as the collection methods 
are simple and artificial insemination is less invasive, cheaper and more 
effective than IVF23. 
 
VI.  SOME TENTATIVE CONCLUSIONS 
   Healthcare decisions in this country seem all too often to result from an 
ad hoc synergy of special interests, without adequate consideration of 
what is in the best interests of either the individual or the community24.  In 
particular, it is often argued that, given the public interest in testing and 
the enormous amount of money to be made from generalized screening, 
the advent of routine genetic screens is simply a matter of time (27).  
Despite calls from several professional bodies that genetic screening 
should be preceded by careful pilot studies (2), the funding for these 
studies is difficult to find.  The only reason the CF follow-up studies were 
commissioned was at the behest of the ELSI committee of the HGP, itself a 
highly unusual and perhaps temporary entity. 
   To summarize, I have tried to establish the following points which must 
be considered when discussing genetic screening of the general 
population: 
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1) Currently, the data we need to assess the diagnostic accuracy 
for most genetic conditions is simply not available.  Moreover, it is 
difficult to secure the funding needed for such studies. 
 
2) Members of the general public will nevertheless perceive testing 
 as diagnostically accurate, particularly if tests are offered as a  
routine part of care by their physician.  This will, in turn, drive the 
 development of more and more genetic tests by private 
 companies interested in the enormous profits to be had from  
screening of the general public. 
 
 3) It is very difficult (though not impossible) to educate people 
 about the implications of genetic results, especially given the 
 current dearth of trained counselors.  It is even more difficult to 
 insure that they retain the information for the extended  periods of 
time often necessary to make appropriate lifestyle or  treatment 
decisions. 
   So, what can we conclude about genetic screening of the general 
population?  I would like to offer some tentative conclusions based on the 
two notions of accuracy I have distinguished: 
1) Individual patients are simply not in a position to evaluate the  
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diagnostic import of genetic tests.  As individuals, they can not 
assess population level phenomena and as non-experts, they can 
not be expected to follow all the technical minutia.  The situation 
seems analogous to the public release of new drugs: patients might 
be interested in trying a new drug but we typically do not allow this 
until we have had a chance to carefully assess its effectiveness and 
possible side effects.  Genetic screening of the general population 
of adults should fall in the same category.  To be sure, there will be 
special situations -- for people in high risk populations, we have 
more data on the distribution of causal factors and thus a better 
grasp of the diagnostic accuracy.  Moreover, a total ban on 
screening would prevent the collection of precisely the data we 
need to evaluate its effectiveness.  However, to the extent that we 
allow screening of members of the population not known to be at 
high risk, it should be for the purpose of data collection only and 
they should be treated as any other experimental subject. 
 
 2)  In cases of pre-natal screening, the same information problems  
 apply as with the general adult population.  However, to the extent 
 that early intervention may be possible, experimental evaluation of 
 early treatments for genetic conditions is certainly justified.   
 Moreover, allowing limited screening of fetuses may be a good 
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 way to generate the data needed to assess the diagnostic 
 accuracy of the screens.  Of course, this would require extensive 
 follow-up after the initial screen to determine which children went 
 on to develop the condition and which did not. 
 
3) Pre-implantation and pre-fertilization screening pose  much less  
 severe problems with respect to diagnostic inaccuracy than those  
associated with other screens of the general population.  This  is  
because a selection often must be made as to which embryo(s) to 
implant or which gamete(s) to employ.  If a decision such as this 
can not be avoided, and if there is no alternative means of 
selection which is more informative, it is less problematic to rely on 
information of uncertain diagnostic accuracy provided by current 
genetic screening techniques.  This is because the decision per se 
does not have to be justified on the basis of the information, since a 
decision of some sort is unavoidable.  Of course, the precise form of 
the decision is justified via the genetic information, but the 
alternative is often to use either arbitrary or morally questionable 
criteria (e.g., sex selection).   Therefore, even if the genetic 
screening turns out to be completely uninformative (which is 
unlikely), it is hard to see how we are any worse off using it in these 
cases. 
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TABLE 1:  PERMUTATIONS OF DIAGNOSTIC CRITERIA  










positive positive positive classic CF 
positive positive negative occurs 
positive negative positive common 
positive negative negative common 
negative positive positive occurs 
negative positive negative occurs 
negative negative positive ? 
negative negative negative health 
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1  For example, The American College of Obstetrics and Gynecology 
includes the offering of prenatal screening as part of the standard of care 
(3).  For a more detailed discussion of the evolution of standard of care as 
it relates to testing, see 4, 5. 
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2 For example, a bilateral radical mastectomy may (or may not) be a 
justified procedure if one is at high risk for breast cancer.  However, such a 
procedure obviously becomes more unwarranted as the prognosis 
becomes less certain. 
 
3 An exception to this is the work of Benjamin Wilfrond (6, 7). 
 
4 This problem is, in some sense, a transient one since it will be corrected 
as our knowledge of the etiology of disease grows.  However, this makes it 
no less serious an issue.  Moreover, the information required to resolve the 
problem will be far more difficult to collect than many currently realize. 
 
5 It should be noted, however, that a small amount of analytical error can 
seriously erode the diagnostic accuracy of a test for rare conditions.  For 
example, even with a relatively common genetic disease such as Cystic 
Fibrosis and a test with a 99% analytical accuracy, a positive result is 
twenty times more likely to be due to test inaccuracy than the presence 
of the gene. 
 
6 For a related discussion concerning the causal nature of disease in 
general and phenylketonuria in particular, see (8, 9) 
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7 Whatever else it might do, widespread use of new cloning technologies 
on humans would be an interesting test of the extent to which human 
traits are the result of genes rather than environments.  By holding the 
genetic background constant and varying both the cellular and maternal 
environment, variation in traits between donor and clone would be 
attributable to differences in the environment -- at least more so than they 
are at present. 
 
8  I do not mean, of course, that it is difficult to calculate a probability, but 
that it is difficult to defend such numbers as being justified, given our 
current state of knowledge about the etiology of most genetic conditions. 
 
9 Of course, the research does not stop here.  Next we would want to 
know (at least) the amino acid sequence of the protein, as well as its 
three-dimensional confirmation, location and function within the cell. 
 
10 The exact incidence figures cited varies from 1/4700 to 1/1000 because 
different authors examine subtly different populations. 
 
11 CFTR is a cAMP mediated chloride channel protein found in the plasma 
membrane.  Defects in this protein result in poor uptake of chloride ions by 
the cells, which results in high levels of chloride in the sweat (10).  Thus, the 
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sweat chloride test is currently considered the gold standard for CF 
diagnosis.  It should be noted that a single mutation, delta F508, seems to 
account for a large majority of CF cases in whites (11). 
 
12 This raises interesting questions about the nature of a disease – should it 
be defined in terms of a symptomology, as was the case in earlier times; 
or should identification of putative casual agents be considered primary 
(see 14)? 
 
13 see (16, 17). Note also that these are known cases of CF - it may be that 
some cases of CF are not detected (due to very mild symptoms, etc.) and 
thus are not reflected in these numbers. 
 
14 This is not a simple matter of patient self-identification.  As anyone who 
has done family history research knows, people rarely have very clear 
ideas about their ancestry more than two or three generations back.  
What is worse, they often have incorrect ideas. 
 
15 New techniques may be able to avoid some of these difficulties, at least 
for single gene conditions, by a direct assay of protein function. It has 
been found that many cells in easily accessible tissue (white blood cells, 
for example) express minute amounts of mRNA from genes that they do 
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not “officially” express.  These cells can be isolated from a blood sample, 
the mRNA amplified and translated into protein, and the protein activity 
directly assayed (18).  Therefore, at least to some extent, it is not necessary 
for us to know precisely which mutation is involved or even its precise 
effect.   
 
16 In fact, given the performance of many physicians on other genetic 
tests like the APC test for familial adenomatus polyposis, the ability of the 
average U.S. physician to act as a genetic counselor without specialized 
training  is in serious question (21). 
 
17 It has even been argued that, on certain conceptions of autonomy, 
patients have an obligation to thoroughly inform themselves about testing 
(22). 
 
18 Women often report that they find it difficult to refuse screening which is 
offered as a routine part of prenatal care -- as with alpha fetaprotein tests 
(4). 
 
19 For example, there is no conclusive evidence that CF screening enables 
effective early intervention, despite much early optimism (7). 
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20 There is the difficulty that cells from the fetuses of earlier pregnancies will 
sometimes still be in the maternal bloodstream (25).  This poses no 
problem, of course, for first pregnancies and future refinements may allow 
us to differentiate between the two cell lines before performing genetic 
analysis. 
 
21   At present, this technique can only be used to detect relatively gross 
abnormalities such as major chromosomal rearrangements or 
aneupolidies. 
 
22 New techniques in embryo collection involve using intrauterine lavage 
to remove an embryo at the blastocyst stage (26).   If these sorts of 
procedures become routine, pre-implantation screening will as well. 
 
23 Intracytoplasmic Sperm Injection (ICSI) even makes screening of 
individual sperm before fertilization a possibility. 
 
24 Wilfrond labels this the “extemporaneous model” of decision making 
and advocates a more “evidentiary model” instead (6, 7). 
   
                                                                                                                                  
